Comparing the current results to its competitors, Optinose Inc reported Revenue increase in the 1 quarter 2025 by 83.27 % year on year, while most of its competitors have experienced contraction in revenues by -5.36 %, achieved in the same quarter.
Optinose Inc 's Comment on Competition and Industry Peers
XHANCE competes with intranasal steroids (INS), oral steroids, monoclonal antibodies, and other medical management products, including locally compounded liquid budesonide used in high-volume nasal rinses. It also competes with surgical procedures, balloon sinus dilation products, and steroid-releasing sinus implants. Key competitive factors include efficacy, safety and tolerability, reliability, convenience of administration, price, and reimbursement. The only other branded INS approved for treating nasal polyps mentioned is Nasonex™, which was marketed by Merck & Co., Inc. before being removed from the prescription market.
September 5, 2024
: Chronic rhinosinusitis (CRS) remains a significant health burden affecting millions globally, often necessitating intricate therapeutic strategies for optimal management. This article discusses the recent findings published in the International Forum of Allergy and Rhinology regarding the efficacy of XHANCE (fluticasone propionate) in patients diagnosed with CRS, with or without a history of prior sinus surgery. These advancements in understanding XHANCE s therapeutic potential signify a pivotal moment for healthcare providers and patients seeking innovative solutions in ENT and allergy-related therapeutic interventions. Chronic rhinosinusitis (CRS) is characterized by prolonged inflammation of the na...
March 15, 2024
In a breakthrough development, the US Food and Drug Administration (FDA) has officially approved XHANCE as the first and only medication indicated for the treatment of Chronic Rhinosinusitis (CRS) without nasal polyps. This remarkable achievement comes as a result of the ReOpen clinical trial program, which demonstrated a statistically significant reduction in symptoms for patients with chronic sinusitis without nasal polyps.The ReOpen Clinical Trial Program:As the inaugural large placebo-controlled clinical trial program of its kind, ReOpen demonstrated a groundbreaking reduction in symptoms among chronic sinusitis patients without nasal polyps. This program has paved the way for a comprehensive understandi...
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Optinose Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Optinose Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
